<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
Covid-19 vaccine developer Novavax’s stock declined by about 7% in after-hours trading on Monday, after the company published a weaker than expected set of Q4 2021 results. While revenue declined by 20% compared to last year, to $222 million due to lower grant-related revenues, net losses widened.
...read full article on Forbes
